OKYO — OKYO Pharma Income Statement
0.000.00%
Last trade - 00:00- $51.24m
- $49.93m
Annual income statement for OKYO Pharma, fiscal year end - March 31st, GBP millions except per share, conversion factor applied.
2020 March 31st | R2021 March 31st | R2022 March 31st | R2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.31 | 2.58 | 6.22 | 13.2 | 15.7 |
| Operating Profit | -1.31 | -2.58 | -6.22 | -13.2 | -15.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.27 | -2.58 | -6.22 | -13.3 | -16.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.21 | -2.56 | -5.43 | -13.3 | -16.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.21 | -2.56 | -5.43 | -13.3 | -16.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.21 | -2.56 | -5.43 | -13.3 | -16.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -8.14 | -16.1 | -0.257 | -0.596 | -0.573 |